Search results
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug
Reuters· 4 days agoThe U.S. Food and Drug Administration has granted accelerated approval French drugmakers Ipsen and...
Ipsen drug for rare liver disease approved by FDA
BioPharma Dive via Yahoo Finance· 3 days agoThe medicine will join Intercept’s Ocaliva as a treatment option for primary biliary cholangitis. Another drug, from the now Gilead-owned CymaBay, could...
Petri Dish: Ipsen’s drug approval; Discovery expands local footprint - Boston Business Journal
The Business Journals· 1 day agoDrug approvals were at the center of two stories this week in the Petri Dish, as we dive into a...
Health Care Roundup: Market Talk
The Wall Street Journal· 3 days agoPublished exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0829 ET – Ipsen’s launch of its rare liver-disease drug in the coming...
Significant Benefit With Liver Transplantation in ACLF
Medscape· 1 day agoLiver transplantation improves survival in patients with acute-on-chronic liver failure (ACLF),...
Seladelpar Shows Clinically Meaningful Improvements in PBC
Medscape· 3 days agoSeladelpar, an investigational selective peroxisome proliferator-activated receptor delta agonist, achieves both biochemical and clinically meaningful improvements in pruritus and liver injury ...
Experts Focus on Quality-of-Life Data in Prostate Cancer
Medscape· 3 days agoSeveral trials presented at ASCO 2024 explored strategies to improve quality of life in patients with prostate cancer.
Tacalyx extends seed funding round to raise over €14m
Pharmaceutical Technology via Yahoo Finance· 2 days agoIn related news in the T cell therapeutics space, French biopharmaceutical company Ipsen recently...
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill...
Benzinga· 3 days agoSkyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced the promotion of Clint ...
FDA OKs Iqirvo, First-in-Class PPAR Treatment for PBC
Medscape· 3 days agoIqirvo (elafibranor) is indicated for adults with primary biliary cholangitis who do not respond to or cannot tolerate ursodeoxycholic acid.